Fuchs Endothelial Corneal Dystrophy Clinical Trial
Official title:
Analysis of the Genotype/Phenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. The French Fuchs' Follow-up Study, F3S
The pathophysiology of the most common corneal endothelial dystrophies (Fuchs' Corneal Endothelial Dystrophy (FECD)) is beginning to be dismembered. One of the most common genetic anomalies is a triplet repetition in one of the introns of the Transcription Factor 4 (TCF4) gene located on chromosome 18. However, the number of repetitions varies greatly from one patient to another.
The intent of that study was to analyse if there is a relationship between the number of triplet repetitions and the rate of disease progression. This knowledge would make it possible to personalize the care. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04440280 -
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
|
Phase 2 | |
Active, not recruiting |
NCT05376176 -
A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
|
Phase 2 | |
Recruiting |
NCT05826353 -
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
|
Phase 3 | |
Recruiting |
NCT04387331 -
The Postoperative Head Position as a Predictor of the Surgical Outcome After DMEK
|
||
Recruiting |
NCT05795699 -
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
|
Phase 3 | |
Active, not recruiting |
NCT04894110 -
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
|
Phase 1 | |
Completed |
NCT04520321 -
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05052554 -
Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3
|
Phase 1 |